FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3047132619> ?p ?o ?g. }

• W3047132619 endingPage "362" @default.
• W3047132619 startingPage "353" @default.
• W3047132619 abstract "The aim of this multi-center retrospective study was to evaluate the incidence of hyperprogressive disease (HPD) after second-line treatment with pembrolizumab in patients (n = 167) with metastatic non-small-cell lung cancer (NSCLC) whose tumors expressed programmed cell death ligand 1 (PD-L1) in ≥ 1% and to search for hematological and imaging biomarkers associated with its development. Prior to chemotherapy, neutrophil : lymphocyte ratio (NLR1) and platelet : lymphocyte ratio (PLR1), and prior to immunotherapy, NLR2 and PLR2 were retrospectively analyzed. The psoas major muscle area (PMMA) was calculated at the L3 position on computed tomography before chemotherapy (PMMA1) and before immunotherapy (PMMA2) (n = 112). Patients with ∆PMMA (1-PMMA2/PMMA1) × 100 ≥ 10% were considered to have sarcopenia (low muscle mass). After treatment with pembrolizumab on the first computerized tomography (CT) scan evaluation, patients were subdivided as follows as: hyperprogressors (HPs), progressors (Ps), non-progressors (NPs) and pseudoprogressors (PPs). HPs had significantly higher ∆PMMA levels, NLR2 and PLR2 than the other patients. Moreover, in multinomial logistic regression analysis, higher levels of ∆PMMA were associated with a decreased likelihood of being a P [odds ratio (OR) = 0·81; 95% confidence interval (CI) = 0·65-0·99; P = 0·047] or an NP (OR = 0·76; 95% CI = 0·62-0·94; P = 0·012) versus an HP. Higher NLRs tended to decrease the likelihood of being a P versus an HP (OR = 0·66; 95% CI = 0·42-1·06; P = 0·09) and significantly decreased the likelihood of being an NP versus an HP (OR = 0·44; 95% CI = 0·28-0·69; P < 0·0001). Our data suggest that a high pre-immunotherapy NLR2 and the presence of sarcopenia are potential risk factors for the development of HPD." @default.
• W3047132619 created "2020-08-10" @default.
• W3047132619 creator A5000744297 @default.
• W3047132619 creator A5001625655 @default.
• W3047132619 creator A5002459136 @default.
• W3047132619 creator A5012205588 @default.
• W3047132619 creator A5017121642 @default.
• W3047132619 creator A5020474393 @default.
• W3047132619 creator A5033198031 @default.
• W3047132619 creator A5036982855 @default.
• W3047132619 creator A5039325468 @default.
• W3047132619 creator A5042304122 @default.
• W3047132619 creator A5042472082 @default.
• W3047132619 creator A5045033727 @default.
• W3047132619 creator A5047307982 @default.
• W3047132619 creator A5054046573 @default.
• W3047132619 creator A5077132227 @default.
• W3047132619 creator A5080640879 @default.
• W3047132619 creator A5081076257 @default.
• W3047132619 creator A5087701893 @default.
• W3047132619 date "2020-08-26" @default.
• W3047132619 modified "2023-10-10" @default.
• W3047132619 title "Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer" @default.
• W3047132619 cites W1982906652 @default.
• W3047132619 cites W2014229457 @default.
• W3047132619 cites W2016722329 @default.
• W3047132619 cites W2040310950 @default.
• W3047132619 cites W2049553585 @default.
• W3047132619 cites W2062627337 @default.
• W3047132619 cites W2075691289 @default.
• W3047132619 cites W2078439148 @default.
• W3047132619 cites W2082976102 @default.
• W3047132619 cites W2101571970 @default.
• W3047132619 cites W2102144390 @default.
• W3047132619 cites W2141269240 @default.
• W3047132619 cites W2154520781 @default.
• W3047132619 cites W2187430385 @default.
• W3047132619 cites W2198093519 @default.
• W3047132619 cites W2221837786 @default.
• W3047132619 cites W2275716355 @default.
• W3047132619 cites W2510363157 @default.
• W3047132619 cites W2553667461 @default.
• W3047132619 cites W2554618897 @default.
• W3047132619 cites W2581283430 @default.
• W3047132619 cites W2584487585 @default.
• W3047132619 cites W2601621622 @default.
• W3047132619 cites W2605497049 @default.
• W3047132619 cites W2737656823 @default.
• W3047132619 cites W2743199111 @default.
• W3047132619 cites W2754223242 @default.
• W3047132619 cites W2779201046 @default.
• W3047132619 cites W2790743957 @default.
• W3047132619 cites W2799808995 @default.
• W3047132619 cites W2799913600 @default.
• W3047132619 cites W2801794411 @default.
• W3047132619 cites W2891266481 @default.
• W3047132619 cites W2899369036 @default.
• W3047132619 cites W2900300395 @default.
• W3047132619 cites W2907814135 @default.
• W3047132619 cites W2909631585 @default.
• W3047132619 cites W2910245285 @default.
• W3047132619 cites W2911557337 @default.
• W3047132619 cites W2919778409 @default.
• W3047132619 cites W2923986778 @default.
• W3047132619 cites W2933875892 @default.
• W3047132619 cites W2944279206 @default.
• W3047132619 cites W2947818354 @default.
• W3047132619 cites W3004487982 @default.
• W3047132619 cites W3005152261 @default.
• W3047132619 doi "https://doi.org/10.1111/cei.13505" @default.
• W3047132619 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7670147" @default.
• W3047132619 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32757277" @default.
• W3047132619 hasPublicationYear "2020" @default.
• W3047132619 type Work @default.
• W3047132619 sameAs 3047132619 @default.
• W3047132619 citedByCount "23" @default.
• W3047132619 countsByYear W30471326192021 @default.
• W3047132619 countsByYear W30471326192022 @default.
• W3047132619 countsByYear W30471326192023 @default.
• W3047132619 crossrefType "journal-article" @default.
• W3047132619 hasAuthorship W3047132619A5000744297 @default.
• W3047132619 hasAuthorship W3047132619A5001625655 @default.
• W3047132619 hasAuthorship W3047132619A5002459136 @default.
• W3047132619 hasAuthorship W3047132619A5012205588 @default.
• W3047132619 hasAuthorship W3047132619A5017121642 @default.
• W3047132619 hasAuthorship W3047132619A5020474393 @default.
• W3047132619 hasAuthorship W3047132619A5033198031 @default.
• W3047132619 hasAuthorship W3047132619A5036982855 @default.
• W3047132619 hasAuthorship W3047132619A5039325468 @default.
• W3047132619 hasAuthorship W3047132619A5042304122 @default.
• W3047132619 hasAuthorship W3047132619A5042472082 @default.
• W3047132619 hasAuthorship W3047132619A5045033727 @default.
• W3047132619 hasAuthorship W3047132619A5047307982 @default.
• W3047132619 hasAuthorship W3047132619A5054046573 @default.
• W3047132619 hasAuthorship W3047132619A5077132227 @default.
• W3047132619 hasAuthorship W3047132619A5080640879 @default.
• W3047132619 hasAuthorship W3047132619A5081076257 @default.
• W3047132619 hasAuthorship W3047132619A5087701893 @default.

• next